Straits Times Index
3,138.90 +31.81 (+1.02%) S&P 500
3,678.43 +92.81 (+2.59%) Dow
29,490.89 +765.38 (+2.66%) Nasdaq
10,815.43 +239.82 (+2.27%) BTC-USD
19,920.43 +754.98 (+3.94%) CMC Crypto 200
452.83 +17.47 (+4.01%)
Kronos Bio, Inc. (KRON)
After hours:
| Previous close | 3.3500 |
| Open | 3.4800 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 800 |
| Day's range | 3.2000 - 3.4000 |
| 52-week range | 2.9600 - 21.1000 |
| Volume | |
| Avg. volume | 234,117 |
| Market cap | 191.88M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9230 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.20 |
- CNW Group
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib. Entospletinib is Kronos Bio's lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute
- Zacks
Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 311.9% upside potential for Kronos Bio, Inc. (KRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks
Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should Know
Kronos Bio, Inc. (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
